Filing of construction permits for a new LFB plant in France
LFB’s « 2020 Plant » Worlwide production from a plant « made in France »
LFB files construction permits
Les Ulis, 1st July 2016 – The biopharmaceutical group LFB announces the filing of construction permits for its « next generation » plant dedicated to the manufacture of plasma-derived medicinal products, which will be settled in the industrial area « Actiparc » within the urban community of Arras (cities of Bailleul-Sir-Berthoult and Saint-Laurent-Blangy).
The challenges of « 2020 Plant ». The LFB group, a French champion in the field of biological medicines, currently runs four plants* in France, among which two are dedicated to the manufacture of plasma-derived medicinal products, in les Ulis and Lille. To ensure its growth and international development, LFB decided to develop its production capacity with a « next generation » plant. « Usine 2020 » should allow a three-fold increase in the manufacture of LFB’s plasma derivatives in the ten years to come, as well as an optimization of production costs to strengthen the group’s competitiveness in a highly technological field and to meet the highest worldwide standards, and then manufacture for the world. This plant was mentioned by French Economy Minister Emmanuel Macron during the parliamentary debates about LFB**, in the course of the review of the « growth and activity » bill, highlighting the growth-promoting aspect of the project.
Key figures of the manufacturing site. The selected site consists of 15 hectares of land with initial use of 9 hectares, and a land reserve of 6 hectares in order to enable future production developments and new production units after 2020. The plant will notably include a manufacturing unit for immunoglobulins, a unit dedicated to fibrinogen, a unit for pharmaceutical formatting for liquid and lyophilized products. The whole project corresponds to an investment of around 300 euromillions.
The choice of Arras. After thorough evaluation of seven potential sites for the plant, in the past two years, LFB chose to locate « Usine 2020 » in the industrial area of Actiparc within the Arras urban community, for its adequacy to the current and future needs of the group, along with a Local Urbanism Plan suited to industrial activity. The proximity of the present LFB site in Lille also was a strong argument in the group’s decision to choose a site in the Nord-Pas-de-Calais-Picardie region.
About LFB:
The LFB group is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group currently markets its products in more than 40 countries around the world with a global turnover of € 501,9 million in 2014.
https://www.groupe-lfb.com/
Contact:
Sandrine Charrières – Communications Director
Tel: +33 (0)1 69 82 72 80
Email: charrieres@lfb.fr
Press contact:
Havas Worldwide
Jeanne Bariller
Tel: +33 (0)6 15 51 49 40
Email: jeanne.bariller@havasww.com